Toxicities of Immunotherapy for the Practitioner - Wikidata - awgldk - TriplyDB

Toxicities of Immunotherapy for the Practitioner

Toxicities of Immunotherapy for the Practitioner

http://www.wikidata.org/entity/Q27008140

about

Improving the clinical impact of biomaterials in cancer immunotherapy.Novel immunotherapies in lymphoid malignancies Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials Imaging Biomarkers in Immunotherapy Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports Immunotherapy for metastatic renal cell carcinoma.Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis.Cancer and physical activity.Dose Titration Algorithm Tuning (DTAT) should supersede 'the' Maximum Tolerated Dose (MTD) in oncology dose-finding trials.Biological agents in gastrointestinal cancers: adverse effects and their management.Assessment of cancer and virus antigens for cross-reactivity in human tissues.The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis.Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Promise of cancer stem cell vaccine.Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy Cancer immunotherapies targeting the PD-1 signaling pathway.A Century of Radiation Therapy and Adaptive Immunity Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors.Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives.Cancer Prevention: Lessons Learned and Future Directions.New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.Is autoimmunity the Achilles' heel of cancer immunotherapy?Immunotherapy for pancreatic cancer.Emodin Inhibits Breast Cancer Growth by Blocking the Tumor-Promoting Feedforward Loop between Cancer Cells and Macrophages.Immune checkpoint inhibitors in lung cancer: past, present and future.Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma.Investigational new drugs for brain cancer.Emerging nanotechnologies for cancer immunotherapy Drug-induced hepatotoxicity in cancer patients - implication for treatment.Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.

P2860

Q26766267-5E0C3DA4-5116-481F-8159-AB79D2171212 Q26777394-B3A62EC5-434E-4C01-B909-66F51DCF5D77 Q28067583-7E01F070-67C4-4BA2-82BF-F6DF0A6C9770 Q28079871-38FD2A5C-E614-4AC2-BA89-49B1D67E91B6 Q28553328-8335D66C-6707-4C7E-90D2-A62D7094A34A Q30234458-82E68B1A-1847-4373-A31F-459390093AD0 Q31005032-4E9F050A-192B-4095-947F-ACF10C918378 Q33434828-05364FD7-7D4F-4691-9660-5AF30CD097F5 Q33608369-EA724914-1B3B-4F81-ADB2-A1B774A7CA12 Q33806551-28D9AEEE-F2EB-4657-A584-1B8E57BD648C Q33895581-C0ADC7D3-ADD9-4C1A-962D-C0ABE5F5BD1E Q36129290-506C673A-BF0E-473B-818C-3D880F483B4F Q36634979-EED81DF7-BACA-400A-91BA-B3391EA8CA9F Q36898404-F728418E-23EE-4A07-8099-C393AA9B7A18 Q36992766-AA01D667-616F-4F32-B596-926444EF8584 Q37114367-6F546C32-76B9-4D88-A840-F899F2516533 Q37320126-191EEC4A-1E60-4BBA-B5C2-6799A1823A38 Q37629874-E97EE465-1471-40FC-AA20-A26A75F0255E Q37737940-F9F3BCAF-7C71-4B65-BF72-7AFD8B2D3D79 Q37747153-CBEA5CA6-BDCB-4C8C-985A-E320A763B39A Q38378516-4E6896B1-17FD-4E9C-AA00-5A757C247B94 Q38586991-F56DA2EB-526C-43C6-90A7-5DAA19912EEF Q38615337-AABC1261-0384-4FA4-946F-A47B9DAF075D Q38632728-8D64E281-322F-4FBA-80CD-74A5E2873521 Q38645803-831BD744-9D1D-4B36-8C0B-A5E83A544116 Q38652183-2E4024F4-044A-4D37-B205-4C1267AEF231 Q38673585-F64D2A3C-5647-4B05-8C5D-53CB51F03391 Q38677432-71AB2916-2E6E-48B4-AF84-CA3DBA80ABE2 Q38687375-CCFE2256-ECE9-4DCF-93EE-0335B5CB5990 Q38722325-E75A3D69-3ADD-450F-8A21-A739D8C78439 Q38769901-77A261B2-5F6A-493F-B6C4-A510EFAF6C30 Q38791209-5ADE485B-C387-47B5-90C8-56EC11040B29 Q38806038-5C54A069-EF81-4BA2-BC0B-9B255E68B4A9 Q38819349-4F947FB3-04AC-4D9F-9E0F-CEF26850BAC8 Q38825707-8EDB68F8-AD1A-4B23-9A6E-E19D8D748733 Q38832510-C086CE10-1F60-4404-A666-10AAE161016F Q38837036-A48204B1-11D9-4A68-993B-C22B747FC5F3 Q38845891-9CBC833C-03AC-4C4D-82BF-EA57C8C351FD Q38870763-1627563C-C477-42B0-A178-DBC2ADCCBAE8 Q38870929-25A7D7F6-DB16-42F7-93CF-A46BF54183F3

P2860

Toxicities of Immunotherapy for the Practitioner

http://www.wikidata.org/entity/Q27008140

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Toxicities of Immunotherapy for the Practitioner

@ast

Toxicities of Immunotherapy for the Practitioner

@en

Toxicities of Immunotherapy for the Practitioner

@nl

type

label

Toxicities of Immunotherapy for the Practitioner

@ast

Toxicities of Immunotherapy for the Practitioner

@en

Toxicities of Immunotherapy for the Practitioner

@nl

prefLabel

Toxicities of Immunotherapy for the Practitioner

@ast

Toxicities of Immunotherapy for the Practitioner

@en

Toxicities of Immunotherapy for the Practitioner

@nl

P1433

Q27008140-D6476941-EEBD-46A9-ABBF-0003635B8B76

P1476

Q27008140-F900550B-4602-49B2-A32A-558524D24551

P2093

Q27008140-330DECBB-C4D0-48A8-97ED-185D8DA0D6F0

Q27008140-33C30DA6-2097-404E-A737-6C58A95C564C

Q27008140-5B0B7106-9954-4ACE-9611-85B0A5A4D941

Q27008140-EC3DCA69-7700-4679-B566-0823A131AB2D

P2860

Q27008140-0084223C-C7AA-4F52-81DF-830E35AB2133

Q27008140-071227B2-CE7B-4C64-8DD3-F38706865E41

Q27008140-073E0EAF-7433-468E-B245-9A5B2A594341

Q27008140-0BF0BB04-469C-4248-8755-01BDFD157FE6

Q27008140-11B36721-CA6D-4913-8F87-A74B8384F41B

Q27008140-13C8E13A-3829-4513-9DF6-805B404BF7D4

Q27008140-150987CD-41CF-44B3-A00B-E22A4EF79946

Q27008140-1DC96A0D-9F9D-48F6-8102-448680AFFC9D

Q27008140-21DD4626-6389-44E3-A71D-3ABC32E4B342

Q27008140-2B2B70FF-7FF9-42D2-B886-14348A658241

P304

Q27008140-159146D3-C827-4B1A-ADB4-FCB49CD3D9B0

P31

Q27008140-92192B45-FC8C-46D6-A906-7554197A3505

P3181

Q27008140-203AA386-EE49-496F-93AE-BA6CFE46EE27

P356

Q27008140-2D524B89-2AE6-458C-B274-3661A52833DF

P407

Q27008140-F774F167-E486-430F-A292-EA05A7613CB0

P433

Q27008140-0F651972-3D53-4478-912F-62AD198E0FDA

P478

Q27008140-2CC69460-5D13-438C-AE81-76DDED0B71EC

P577

Q27008140-EBB3BC02-7546-4453-BC5F-CCF134059351

P698

Q27008140-E7B1A908-4844-4044-8448-695C458B89DB

P921

Q27008140-565E2B50-E8F3-492D-8AF1-FDE841AF0B80

P932

Q27008140-C48411DA-4E38-4A79-99E2-E0B2D4F9CF10

P3181

P356

JCO.2014.60.0379

P1433

Journal of Clinical Oncology

P1476

Toxicities of Immunotherapy for the Practitioner

@en

P2093

J. C. Yang

http://www.w3.org/2001/XMLSchema#string

J. S. Weber

http://www.w3.org/2001/XMLSchema#string

M. B. Atkins

http://www.w3.org/2001/XMLSchema#string

M. L. Disis

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

New perspectives on the role of vitiligo in immune responses to melanoma

Nivolumab plus ipilimumab in advanced melanoma.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

P304

2092-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1371862

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2014.60.0379

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25918278

http://www.w3.org/2001/XMLSchema#string

P921

P932

4881375

http://www.w3.org/2001/XMLSchema#string